Division of Pharmaceutical Research and Development Platform Project for Supporting Drug Discovery and Life Science Research

Outline

Key Fields Drug Discovery & Development(1st)
R&D phase Basic Study, Applied Study, Nonclinical Study/Pre-clinical Study, Clinical Study, Clinical Trials, Post Marketing, Clinical Research, None
Contact
Division of Drug Research, Department of Innovative Drug Discovery and Development (iD3)
TEL: +81-3-6870-2219

Overview

The objective of this program is to establish an innovative process (the Platform for Drug Discovery, Informatics, and Structural Life Science) for steady and immediate linkage of early-stage drug discovery and medical technologies to therapeutic applications by providing and sharing technological infrastructure which can be utilized in the process of drug discovery. Three collaboration platforms (analysis, control, and information) cooperate to support a wide range of life science researchers in a multifaceted manner through utilization of common facilities and equipment along with the provision of technology, including the world's highest-leveled synchrotron radiation facilities, state-of-the-art cryo-electron microscopy (cryo-EM), compound libraries, high-throughput screening (HTS) centers, protein integrated database, and next-generation sequencer.

This program provides research coordination, such as utilization of the Platform or the proposal of collaborative studies, as needed. It also implements research, which aims future sharing or support, regarding further advancement of technologies, facilities, and equipment.

figure

Management and Evaluation Framework

PS (Program Supervisor)
  • Haruki Nakamura, Ph. D., Director, Institute for Protein Research, Osaka University
PO (Program Officer)
  • Tsuyoshi Inoue, Ph.D., Professor, Graduate School of Engineering, Osaka University
  • Midori Takimoto-Kamimura, Distinguished research scientist Teijin Institute for Biomedical research
  • Haruhiko Koseki, M.D., Ph.D., Group Director, Laboratory for Developmental Genetics, RIKEN Center for Integrative Sciences
  • Hirosato Kondo, Ph.D., Director, Center for Drug Design Research, National Institutes of Biomedical Innovation, Health and Nutrition
  • Shigenori Tanaka, Ph.D., Professor, Graduate School of System Informatics, Kobe University
  • Motowo Nakajima, Ph.D., Director & Senior Managing Executive Officer SBI Pharmaceuticals Co., Ltd.
  • Haruki Nakamura, Ph. D., Director, Institute for Protein Research, Osaka University

Last updated 2017.7.7